Loading patent…
AssigneeGlaxosmithkline Biologicals SA
InventorsCristina ALAIMO, Maria Paula CARRANZA SANDMEIER, Michael Thomas KOWARIK, Patricia MARTIN KILLIAS
Estimating the term…
The present invention relates to the field of immunogenic compositions and vaccines, their manufacture, host cells which can be used in their manufacture and the use of such immunogenic compositions and vaccines in medicine. More particularly, it relates to an immunogenic composition comprising a Klebsiella pneumoniae O1v1 O-antigen polysaccharide conjugate, a Klebsiella pneumoniae O2a O-antigen polysaccharide conjugate, a Klebsiella pneumoniae O2afg O-antigen polysaccharide conjugate and a Klebsiella pneumoniae O3b O-antigen polysaccharide conjugate, wherein each of the Klebsiella pneumoniae O1v1, O2a, O2afg and O3b O-antigen polysaccharides are individually conjugated to a carrier protein (e.g. a detoxified Exotoxin A of Pseudomonas aeruginosa (EPA)) wherein the Klebsiella pneumoniae O3b O-antigen polysaccharide conjugate is present in said immunogenic composition at a higher saccharide dose than at least one of the Klebsiella pneumoniae O1v1 O-antigen polysaccharide conjugate, Klebsiella pneumoniae O2a O-antigen polysaccharide conjugate or Klebsiella pneumoniae O2afg O-antigen polysaccharide conjugate.
An immunogenic composition comprising a Klebsiella pneumoniae O1v1 O-antigen polysaccharide conjugate, a Klebsiella pneumoniae O2a O-antigen polysaccharide conjugate, a Klebsiella pneumoniae O2afg O-antigen polysaccharide conjugate, and a Klebsiella pneumoniae O3b O-antigen polysaccharide conjugate, wherein each of the Klebsiella pneumoniae O1v1, O2a, O2afg, and O3b O-antigen polysaccharides are individually conjugated to a carrier protein, wherein the Klebsiella pneumoniae O3b O-antigen polysaccharide conjugate is present in said immunogenic composition at at least a 2-fold higher saccharide dose than each of the Klebsiella pneumoniae O1v1 O-antigen polysaccharide conjugate, the Klebsiella pneumoniae O2a O-antigen polysaccharide conjugate, and the Klebsiella pneumoniae O2afg O-antigen polysaccharide conjugate saccharide doses.
Dependencies are inferred from the claim text.